Evidence map›Paper›PMID 36245600›Full record

ReviewJournal of thoracic disease2022

Ancillary treatment of patients with lung disease due to non-tuberculous mycobacteria: a narrative review.

Artmis Youssefnia, Alicia Pierre, Jeffrey M Hoder, Michelle MacDonald, Monica J B Shaffer, Jessica Friedman, Philip S Mehler, Amanda Bontempo, Francisco C N da Silva, Edward D Chan

Open access · diamondAbstract readReview
In one paragraph

Review in Journal of thoracic disease, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 14 citations in OpenAlex.

  1. Predictors of treatment initiation in nontuberculous mycobacterial pulmonary disease: a real-life retrospective analysis.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Observational
  2. Review
  3. Article
  4. Comprehensive Management Algorithm forAnnals of the American Thoracic Society · 2025
    Review
  5. Article
  6. Article
  7. Article
  8. Growing from common ground: nontuberculous mycobacteria and bronchiectasis.European respiratory review : an official journal of the European Respiratory Society · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 1 country.

Artmis YoussefniaDepartment of Physical Therapy at Rusk Rehabilitation, New York University Langone Health, New York, NY, USA.
Alicia PierreDepartment of Physical Therapy at Rusk Rehabilitation, New York University Langone Health, New York, NY, USA.
Jeffrey M HoderDoctor of Physical Therapy Program, Duke University, Durham, NC, USA.
Michelle MacDonaldDepartment of Nutrition, National Jewish Health, Denver, CO, USA.
Monica J B ShafferSpeech Therapy, National Jewish Health, Denver, CO, USA.
Jessica FriedmanUniversity of Denver, Denver, CO, USA.
Philip S MehlerDepartment of Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
Amanda BontempoPerlmutter Cancer Center at New York University Langone Health, New York, NY, USA.
Francisco C N da SilvaDepartment of Physical Therapy at Rusk Rehabilitation, New York University Langone Health, New York, NY, USA.
Edward D ChanProgram in Cell Biology, National Jewish Health, Denver, CO, USA.
New York University · USUniversity of Colorado Denver · USDuke University · USNational Jewish Health · USNYU Langone Health · USRusk Rehabilitation · USUniversity of Denver · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and Objective: Non-tuberculous mycobacterial lung disease (NTM-LD) manifests with bronchiectasis, inflammatory bronchiolitis, nodules, and/or cavitation. Bronchiectasis is characterized by permanently dilated airways wherein mucus accumulates, creating a vicious cycle of chronic injurious inflammation and recurrent infections. While antibiotics are an important part of the treatment of NTM-LD, airway clearance techniques to mitigate this pathogenic mechanism of bronchiectasis as well as other ancillary measures are also important components of NTM-LD treatment. The objective of this contemporaneous Narrative Review is to emphasize the importance of such ancillary measures. Methods: We searched PubMed for the key words of "airway clearance", "pulmonary rehabilitation", "nutrition", "swallowing dysfunction", "gastroesophageal reflux", "vestibular dysfunction", or "cochlear dysfunction" with that of "non-tuberculous mycobacterial lung disease", "bronchiectasis", or "respiratory disease". The bibliographies of identified articles were further searched for relevant articles not previously identified. Each relevant article was reviewed by one or more of the authors and a narrative review was composed. Key Content and Findings: Herein, we discuss five ancillary treatment measures that are pertinent to patients with bronchiectasis and NTM-LD: (I) airway clearance; (II) physical and pulmonary rehabilitation; (III) nutrition; (IV) diagnosis and mitigation of swallowing dysfunction and of gastroesophageal reflux disease (GERD); and (V) minimization of vestibular and cochlear dysfunction associated with some anti-NTM drugs. Conclusions: While antibiotics is often the central focus of treatment of NTM-LD, given its propensity for recurrent and recalcitrant infection, other ancillary measures to break the vicious cycle of injurious inflammation and infection should also be emphasized to optimize treatment success.

Indexed as

Airway clearanceaspirationbronchiectasisgastroesophageal refluxnutritionvestibular dysfunction

Identifiers

PMID36245600
PMCPMC9562528
OpenAlexW4293412912

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.